The TAM receptor protein tyrosine kinases — TYRO3, AXL and MER — have important roles in the immune, nervous, reproductive and vascular systems. Two closely related proteins — growth-arrest-specific 6 (GAS6) and protein S — function as TAM ligands.
Mutant mice that lack all three TAM receptors are viable, but exhibit a plethora of phenotypes, all of which appear to be degenerative rather than developmental in nature.
Mice deficient in all three TAM receptors develop a severe lymphoproliferative disorder accompanied by broad-spectrum autoimmune disease. These immune phenotypes reflect a loss of TAM function in dendritic cells (DCs), macrophages and natural killer (NK) cells, rather than in lymphocytes.
Recent studies have revealed that autoimmunity in TAM triple mutants results from the loss of TAM-mediated regulation of two phenomena: the inhibition of the innate inflammatory response to pathogens by DCs and macrophages, and the phagocytosis of apoptotic cells by these antigen-presenting cells.
Both TAM-mediated inhibition of inflammation and TAM-mediated stimulation of NK-cell differentiation require an intimate signalling interaction between TAM receptors and cytokine receptors, and this may prove to be a general feature of TAM action in the immune system.
The discovery of TAM receptor function illuminates novel targets for therapeutic intervention. Future studies focused on the selective activation or inhibition of this receptor family may lead to new therapies for chronic inflammatory diseases and new vaccine adjuvants, respectively.
Recent studies have revealed that the TAM receptor protein tyrosine kinases — TYRO3, AXL and MER — have pivotal roles in innate immunity. They inhibit inflammation in dendritic cells and macrophages, promote the phagocytosis of apoptotic cells and membranous organelles, and stimulate the maturation of natural killer cells. Each of these phenomena may depend on a cooperative interaction between TAM receptor and cytokine receptor signalling systems. Although its importance was previously unrecognized, TAM signalling promises to have an increasingly prominent role in studies of innate immune regulation.
This is a preview of subscription content
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Manning, G., Whyte, D. B., Martinez, R., Hunter, T. & Sudarsanam, S. The protein kinase complement of the human genome. Science 298, 1912–1934 (2002).
Bublil, E. M. & Yarden, Y. The EGF receptor family: spearheading a merger of signaling and therapeutics. Curr. Opin. Cell Biol. 19, 124–134 (2007).
Pasquale, E. B. Eph receptor signalling casts a wide net on cell behaviour. Nature Rev. Mol. Cell Biol. 6, 462–475 (2005).
Lai, C. & Lemke, G. An extended family of protein-tyrosine kinase genes differentially expressed in the vertebrate nervous system. Neuron 6, 691–704 (1991). This study first identified the TAM receptors as a distinct receptor PTK subfamily.
O'Bryan, J. P. et al. axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol. Cell. Biol. 11, 5016–5031 (1991).
Lapraz, F. et al. RTK and TGF-β signaling pathways genes in the sea urchin genome. Dev. Biol. 300, 132–152 (2006).
Sasaki, T. et al. Structural basis for Gas6–Axl signalling. EMBO J. 25, 80–87 (2006).
Stitt, T. N. et al. The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases. Cell 80, 661–670 (1995). This study reports the identification of two ligands for TAM receptors.
Nagata, K. et al. Identification of the product of growth arrest-specific gene 6 as a common ligand for Axl, Sky, and Mer receptor tyrosine kinases. J. Biol. Chem. 271, 30022–30027 (1996).
Prasad, D. et al. TAM receptor function in the retinal pigment epithelium. Mol. Cell. Neurosci. 33, 96–108 (2006).
Uehara, H. & Shacter, E. Auto-oxidation and oligomerization of protein S on the apoptotic cell surface is required for Mer tyrosine kinase-mediated phagocytosis of apoptotic cells. J. Immunol. 180, 2522–2530 (2008).
Rezende, S. M., Simmonds, R. E. & Lane, D. A. Coagulation, inflammation, and apoptosis: different roles for protein S and the protein S–C4b binding protein complex. Blood 103, 1192–1201 (2004).
Huang, M. et al. Structural basis of membrane binding by Gla domains of vitamin K-dependent proteins. Nature Struct. Biol. 10, 751–756 (2003).
Nakano, T. et al. Requirement of γ-carboxyglutamic acid residues for the biological activity of Gas6: contribution of endogenous Gas6 to the proliferation of vascular smooth muscle cells. Biochem. J. 323, 387–392 (1997).
Hasanbasic, I., Rajotte, I. & Blostein, M. The role of γ-carboxylation in the anti-apoptotic function of Gas6. J. Thromb. Haemost. 3, 2790–2797 (2005).
Benzakour, O. & Kanthou, C. The anticoagulant factor, protein S, is produced by cultured human vascular smooth muscle cells and its expression is up-regulated by thrombin. Blood 95, 2008–2014 (2000).
Anderson, H. A. et al. Serum-derived protein S binds to phosphatidylserine and stimulates the phagocytosis of apoptotic cells. Nature Immunol. 4, 87–91 (2003). This work identified the TAM ligand protein S as the factor responsible for serum-stimulated phagocytosis of apoptotic cells.
Sasaki, T. et al. Crystal structure of a C-terminal fragment of growth arrest-specific protein Gas6. Receptor tyrosine kinase activation by laminin G-like domains. J. Biol. Chem. 277, 44164–44170 (2002).
Greenman, C. et al. Patterns of somatic mutation in human cancer genomes. Nature 446, 153–158 (2007).
Lu, Q. et al. Tyro-3 family receptors are essential regulators of mammalian spermatogenesis. Nature 398, 723–728 (1999). This study documented the progressive degeneration of germ cells in the TAM triple mutant mice.
Lu, Q. & Lemke, G. Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family. Science 293, 306–311 (2001). This study demonstrated that TAM-deficient mice develop severe lymphoproliferation and systemic autoimmunity.
Caraux, A. et al. Natural killer cell differentiation driven by Tyro3 receptor tyrosine kinases. Nature Immunol. 7, 747–754 (2006). This work showed that the TAM receptors are required for NK-cell differentiation and maturation.
Angelillo-Scherrer, A. et al. Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis. Nature Med. 7, 215–221 (2001).
Yanagita, M. et al. Essential role of Gas6 for glomerular injury in nephrotoxic nephritis. J. Clin. Invest. 110, 239–246 (2002).
Rothlin, C. V., Ghosh, S., Zuniga, E. I., Oldstone, M. B. & Lemke, G. TAM receptors are pleiotropic inhibitors of the innate immune response. Cell 131, 1124–1136 (2007). This study identified a new negative regulatory pathway driven by the TAM receptor family, and established its role as an inhibitor of both TLR- and cytokine-driven immune responses in APCs.
Camenisch, T. D., Koller, B. H., Earp, H. S. & Matsushima, G. K. A novel receptor tyrosine kinase, Mer, inhibits TNF-α production and lipopolysaccharide-induced endotoxic shock. J. Immunol. 162, 3498–3503 (1999).
Tibrewal, N. et al. Autophosphorylation docking site Tyr-867 in Mer receptor tyrosine kinase allows for dissociation of multiple signaling pathways for phagocytosis of apoptotic cells and down-modulation of lipopolysaccharide-inducible NF-κB transcriptional activation. J. Biol. Chem. 283, 3618–3627 (2008).
Wormald, S. & Hilton, D. J. The negative regulatory roles of suppressor of cytokine signaling proteins in myeloid signaling pathways. Curr. Opin. Hematol. 14, 9–15 (2007).
Yoshimura, A., Nishinakamura, H., Matsumura, Y. & Hanada, T. Negative regulation of cytokine signaling and immune responses by SOCS proteins. Arthritis Res. Ther. 7, 100–110 (2005).
Levy, D. E. & Darnell, J. E. Jr. Stats: transcriptional control and biological impact. Nature Rev. Mol. Cell Biol. 3, 651–662 (2002).
Sharif, M. N. et al. Twist mediates suppression of inflammation by type I IFNs and Axl. J. Exp. Med. 203, 1891–1901 (2006).
Wang, H. et al. Immunoexpression of Tyro 3 family receptors — Tyro 3, Axl, and Mer — and their ligand Gas6 in postnatal developing mouse testis. J. Histochem. Cytochem. 53, 1355–1364 (2005).
Nakanishi, Y. & Shiratsuchi, A. Phagocytic removal of apoptotic spermatogenic cells by Sertoli cells: mechanisms and consequences. Biol. Pharm. Bull. 27, 13–16 (2004).
Nakagawa, A., Shiratsuchi, A., Tsuda, K. & Nakanishi, Y. In vivo analysis of phagocytosis of apoptotic cells by testicular Sertoli cells. Mol. Reprod. Dev. 71, 166–177 (2005).
Ueno, H. & Mori, H. Morphometrical analysis of Sertoli cell ultrastructure during the seminiferous epithelial cycle in rats. Biol. Reprod. 43, 769–776 (1990).
Young, R. W. & Bok, D. Participation of the retinal pigment epithelium in the rod outer segment renewal process. J. Cell Biol. 42, 392–403 (1969).
D'Cruz, P. M. et al. Mutation of the receptor tyrosine kinase gene Mertk in the retinal dystrophic RCS rat. Hum. Mol. Genet. 9, 645–651 (2000).
Nandrot, E. et al. Homozygous deletion in the coding sequence of the c-mer gene in RCS rats unravels general mechanisms of physiological cell adhesion and apoptosis. Neurobiol. Dis. 7, 586–599 (2000).
Duncan, J. L. et al. An RCS-like retinal dystrophy phenotype in mer knockout mice. Invest. Ophthalmol. Vis. Sci. 44, 826–838 (2003).
Gal, A. et al. Mutations in MERTK, the human orthologue of the RCS rat retinal dystrophy gene, cause retinitis pigmentosa. Nature Genet. 26, 270–271 (2000).
Tschernutter, M. et al. Clinical characterisation of a family with retinal dystrophy caused by mutation in the Mertk gene. Br. J. Ophthalmol. 90, 718–723 (2006). References 37 to 41 identified the essential role of MER in retinal homeostasis and phagocytosis in mice, rats and humans.
Scott, R. S. et al. Phagocytosis and clearance of apoptotic cells is mediated by MER. Nature 411, 207–211 (2001). This is the first study that demonstrated the importance of the TAM receptor MER in the clearance of apoptotic cells by macrophages.
Cohen, P. L. et al. Delayed apoptotic cell clearance and lupus-like autoimmunity in mice lacking the c-mer membrane tyrosine kinase. J. Exp. Med. 196, 135–140 (2002).
Seitz, H. M., Camenisch, T. D., Lemke, G., Earp, H. S. & Matsushima, G. K. Macrophages and dendritic cells use different Axl/Mertk/Tyro3 receptors in clearance of apoptotic cells. J. Immunol. 178, 5635–5642 (2007).
Mahoney, J. A. & Rosen, A. Apoptosis and autoimmunity. Curr. Opin. Immunol. 17, 583–588 (2005).
Marshak-Rothstein, A. Toll-like receptors in systemic autoimmune disease. Nature Rev. Immunol. 6, 823–835 (2006).
Baccala, R., Hoebe, K., Kono, D. H., Beutler, B. & Theofilopoulos, A. N. TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity. Nature Med. 13, 543–551 (2007).
Baumann, I. et al. Impaired uptake of apoptotic cells into tingible body macrophages in germinal centers of patients with systemic lupus erythematosus. Arthritis Rheum. 46, 191–201 (2002).
Gaipl, U. S. et al. Clearance of apoptotic cells in human SLE. Curr. Dir. Autoimmun. 9, 173–187 (2006).
Stuart, L. M. et al. Inhibitory effects of apoptotic cell ingestion upon endotoxin-driven myeloid dendritic cell maturation. J. Immunol. 168, 1627–1635 (2002).
Sauter, B. et al. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J. Exp. Med. 191, 423–434 (2000).
Ravichandran, K. S. “Recruitment signals” from apoptotic cells: invitation to a quiet meal. Cell 113, 817–820 (2003).
Ogden, C. A. et al. Enhanced apoptotic cell clearance capacity and B cell survival factor production by IL-10-activated macrophages: implications for Burkitt's lymphoma. J. Immunol. 174, 3015–3023 (2005).
Lingnau, M., Hoflich, C., Volk, H. D., Sabat, R. & Docke, W. D. Interleukin-10 enhances the CD14-dependent phagocytosis of bacteria and apoptotic cells by human monocytes. Hum. Immunol. 68, 730–738 (2007).
Jung, M. et al. Expression profiling of IL-10-regulated genes in human monocytes and peripheral blood mononuclear cells from psoriatic patients during IL-10 therapy. Eur. J. Immunol. 34, 481–493 (2004).
Sen, P. et al. Apoptotic cells induce Mer tyrosine kinase-dependent blockade of NF-κB activation in dendritic cells. Blood 109, 653–660 (2007).
Wallet, M. A. et al. MerTK is required for apoptotic cell-induced T cell tolerance. J. Exp. Med. 205, 219–232 (2008).
Wu, Y., Tibrewal, N. & Birge, R. B. Phosphatidylserine recognition by phagocytes: a view to a kill. Trends Cell Biol. 16, 189–197 (2006).
Miyanishi, M. et al. Identification of Tim4 as a phosphatidylserine receptor. Nature 450, 435–439 (2007).
Park, D. et al. BAI1 is an engulfment receptor for apoptotic cells upstream of the ELMO/Dock180/Rac module. Nature 450, 430–434 (2007).
Finnemann, S. C. & Nandrot, E. F. MerTK activation during RPE phagocytosis in vivo requires αVβ5 integrin. Adv. Exp. Med. Biol. 572, 499–503 (2006).
Mahajan, N. P. & Earp, H. S. An SH2 domain-dependent, phosphotyrosine-independent interaction between Vav1 and the Mer receptor tyrosine kinase: a mechanism for localizing guanine nucleotide-exchange factor action. J. Biol. Chem. 278, 42596–42603 (2003).
Lodoen, M. B. & Lanier, L. L. Natural killer cells as an initial defense against pathogens. Curr. Opin. Immunol. 18, 391–398 (2006).
Smyth, M. J. et al. Activation of NK cell cytotoxicity. Mol. Immunol. 42, 501–510 (2005).
Screpanti, V., Wallin, R. P., Grandien, A. & Ljunggren, H. G. Impact of FASL-induced apoptosis in the elimination of tumor cells by NK cells. Mol. Immunol. 42, 495–499 (2005).
Screpanti, V., Wallin, R. P., Ljunggren, H. G. & Grandien, A. A central role for death receptor-mediated apoptosis in the rejection of tumors by NK cells. J. Immunol. 167, 2068–2073 (2001).
Lieberman, J. The ABCs of granule-mediated cytotoxicity: new weapons in the arsenal. Nature Rev. Immunol. 3, 361–370 (2003).
Trapani, J. A. & Smyth, M. J. Functional significance of the perforin/granzyme cell death pathway. Nature Rev. Immunol. 2, 735–747 (2002).
Arase, H., Arase, N. & Saito, T. Interferon γ production by natural killer (NK) cells and NK1.1+ T cells upon NKR-P1 cross-linking. J. Exp. Med. 183, 2391–2396 (1996).
Gosselin, P. et al. Induction of DAP12 phosphorylation, calcium mobilization, and cytokine secretion by Ly49H. J. Leukoc. Biol. 66, 165–171 (1999).
Ortaldo, J. R. & Young, H. A. Expression of IFN-γ upon triggering of activating Ly49D NK receptors in vitro and in vivo: costimulation with IL-12 or IL-18 overrides inhibitory receptors. J. Immunol. 170, 1763–1769 (2003).
Raulet, D. H., Vance, R. E. & McMahon, C. W. Regulation of the natural killer cell receptor repertoire. Annu. Rev. Immunol. 19, 291–330 (2001).
Vivier, E., Nunès, J. A. & Vély, F. Natural killer cell signaling pathways. Science 306, 1517–1519 (2004).
Lanier, L. L. NK cell recognition. Annu. Rev. Immunol. 23, 225–274 (2005).
Roth, C., Rothlin, C., Riou, S., Raulet, D. H. & Lemke, G. Stromal-cell regulation of natural killer cell differentiation. J. Mol. Med. 85, 1047–1056 (2007).
Behrens, E. M. et al. The mer receptor tyrosine kinase: expression and function suggest a role in innate immunity. Eur. J. Immunol. 33, 2160–2167 (2003).
Kennedy, M. K. et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J. Exp. Med. 191, 771–780 (2000).
Cooper, M. A. et al. In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. Blood 100, 3633–3638 (2002).
Prlic, M., Blazar, B. R., Farrar, M. A. & Jameson, S. C. In vivo survival and homeostatic proliferation of natural killer cells. J. Exp. Med. 197, 967–976 (2003).
Koka, R. et al. Interleukin (IL)-15Rα-deficient natural killer cells survive in normal but not IL-15Rα-deficient mice. J. Exp. Med. 197, 977–984 (2003).
Dubois, S., Mariner, J., Waldmann, T. A. & Tagaya, Y. IL-15Rα recycles and presents IL-15 in trans to neighboring cells. Immunity 17, 537–547 (2002).
Budagian, V. et al. A promiscuous liaison between IL-15 receptor and Axl receptor tyrosine kinase in cell death control. EMBO J. 24, 4260–4270 (2005). This study documented the IL-15-induced transactivation of the TAM receptor AXL and showed both physical and functional crosstalk between the IL-15 receptor and AXL.
Broad, A., Jones, D. E. & Kirby, J. A. Toll-like receptor (TLR) response tolerance: a key physiological “damage limitation” effect and an important potential opportunity for therapy. Curr. Med. Chem. 13, 2487–2502 (2006).
Dalpke, A. H., Lehner, M. D., Hartung, T. & Heeg, K. Differential effects of CpG-DNA in Toll-like receptor-2/-4/-9 tolerance and cross-tolerance. Immunology 116, 203–212 (2005).
Borgel, D. et al. Elevated growth-arrest-specific protein 6 plasma levels in patients with severe sepsis. Crit. Care Med. 34, 219–222 (2006).
Meesters, E. W. et al. The inflammation and coagulation cross-talk in patients with systemic lupus erythematosus. Blood Coagul. Fibrinolysis 18, 21–28 (2007).
Brouwer, J. L., Bijl, M., Veeger, N. J., Kluin-Nelemans, H. C. & van der Meer, J. The contribution of inherited and acquired thrombophilic defects, alone or combined with antiphospholipid antibodies, to venous and arterial thromboembolism in patients with systemic lupus erythematosus. Blood 104, 143–148 (2004).
Song, K. S., Park, Y. S. & Kim, H. K. Prevalence of anti-protein S antibodies in patients with systemic lupus erythematosus. Arthritis Rheum. 43, 557–560 (2000).
Kulman, J. D. et al. Vitamin K-dependent proteins in Ciona intestinalis, a basal chordate lacking a blood coagulation cascade. Proc. Natl Acad. Sci. USA 103, 15794–15799 (2006).
Liongue, C. & Ward, A. C. Evolution of Class I cytokine receptors. BMC Evol. Biol. 7, 120 (2007).
Krause, C. D. & Pestka, S. Evolution of the Class 2 cytokines and receptors, and discovery of new friends and relatives. Pharmacol. Ther. 106, 299–346 (2005).
Melaragno, M. G. et al. Gas6 inhibits apoptosis in vascular smooth muscle: role of Axl kinase and Akt. J. Mol. Cell. Cardiol. 37, 881–887 (2004).
Korshunov, V. A., Daul, M., Massett, M. P. & Berk, B. C. Axl mediates vascular remodeling induced by deoxycorticosterone acetate-salt hypertension. Hypertension 50, 1057–1062 (2007).
Korshunov, V. A., Mohan, A. M., Georger, M. A. & Berk, B. C. Axl, a receptor tyrosine kinase, mediates flow-induced vascular remodeling. Circ. Res. 98, 1446–1452 (2006).
Angelillo-Scherrer, A. et al. Role of Gas6 receptors in platelet signaling during thrombus stabilization and implications for antithrombotic therapy. J. Clin. Invest. 115, 237–246 (2005).
Gould, W. R. et al. Gas6 receptors Axl, Sky and Mer enhance platelet activation and regulate thrombotic responses. J. Thromb. Haemost. 3, 733–741 (2005).
Angelillo-Scherrer, A. et al. Role of Gas6 in erythropoiesis and anemia in mice. J. Clin. Invest. 118, 583–596 (2008).
Graham, D. K. et al. Ectopic expression of the proto-oncogene Mer in pediatric T-cell acute lymphoblastic leukemia. Clin. Cancer Res. 12, 2662–2669 (2006).
Keating, A. K. et al. Lymphoblastic leukemia/lymphoma in mice overexpressing the Mer (MerTK) receptor tyrosine kinase. Oncogene 25, 6092–6100 (2006).
Nakamura, Y. S. et al. Tyro 3 receptor tyrosine kinase and its ligand, Gas6, stimulate the function of osteoclasts. Stem Cells 16, 229–238 (1998).
Katagiri, M. et al. Mechanism of stimulation of osteoclastic bone resorption through Gas6/Tyro 3, a receptor tyrosine kinase signaling, in mouse osteoclasts. J. Biol. Chem. 276, 7376–7382 (2001).
Shankar, S. L. et al. The growth arrest-specific gene product Gas6 promotes the survival of human oligodendrocytes via a phosphatidylinositol 3-kinase-dependent pathway. J. Neurosci. 23, 4208–4218 (2003).
Shankar, S. L. et al. Gas6/Axl signaling activates the phosphatidylinositol 3-kinase/Akt1 survival pathway to protect oligodendrocytes from tumor necrosis factor α-induced apoptosis. J. Neurosci. 26, 5638–5648 (2006).
Shimojima, M., Ikeda, Y. & Kawaoka, Y. The mechanism of Axl-mediated Ebola virus infection. J. Infect. Dis. 196 (Suppl. 2), 259–263 (2007).
Shimojima, M. et al. Tyro3 family-mediated cell entry of Ebola and Marburg viruses. J. Virol. 80, 10109–10116 (2006).
Work in the authors' laboratory is supported by grants from the Lupus Research Institute and the US National Institutes of Health (G.L.), by the Salk Institute (G.L. and C.V.R.) and by the Pew Latin American Fellows Program (C.V.R.).
- Natural killer (NK) cells
NK cells are lymphoid cells capable of lysing bacteria- and virus-infected cells, as well as many tumour cells, without prior sensitization. They have important roles in combating infections, in the immune surveillance of cancer and in host-versus-graft rejection.
- Toll-like receptors
(TLRs). Pattern-recognition receptors that recognize molecules — such as the lipopolysaccharide of bacterial cell walls, the unmethylated CpG-containing deoxynucleotides of bacterial DNA and the double-stranded RNAs of viruses — that are broadly shared by pathogens but not by host cells. Pathogen activation of TLRs initiates the innate immune response in dendritic cells and macrophages.
- SOCS proteins
(Suppressor of cytokine signalling proteins). SOCS proteins inhibit STAT (signal-transducer and activator of transcription) phosphorylation by binding and inhibiting JAKs (Janus-family kinases) and/or competing with STATs for phosphotyrosine binding sites on cytokine receptors. They also inhibit signal transducers downstream of Toll-like receptor activation.
(Signal transducers and activators of transcription). STATs are latent cytoplasmic transcription factors that upon phosphorylation, typically by Janus-family kinases (JAKs), are activated. They then translocate to the nucleus, where they drive the transcription of their target genes. The signal transduction pathways downstream of many cytokine receptors depend on STAT protein activation.
About this article
Journal of Translational Medicine (2021)
Communications Biology (2021)
Cell Death & Disease (2021)
Combination of a T cell activating therapy and anti-phosphatidylserine enhances anti-tumour immune responses in a HPV16 E7-expressing C3 tumour model
Scientific Reports (2021)